HOME >> MEDICINE >> NEWS
ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

Results suggest new hope for patients with refractory chronic lymphocytic leukemia Data to support BLA submission

BARCELONA, SPAIN, June 12 ---ILEXTM Oncology, Inc. (NASDAQ: ILXO) and LeukoSite, Inc. (NASDAQ: LKST) today announced final results from an international, multi-center, pivotal Phase II clinical trial of CAMPATHR for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) who are refractory to fludarabine. Results of the trial were presented this weekend at the 4th Congress of the European Haematology Association (EHA) by Michael J. Keating, MB, BS, of the M.D. Anderson Cancer Center, one of the trial's principal investigators and an internationally recognized expert in CLL. The companies plan to submit a Biologics License Application (BLA) based largely on these results later this year.

"The results of this trial are encouraging," said Dr. Keating, Associate Head for Clinical Research and Professor of Medicine and internist for the Department of Leukemia at M.D. Anderson Cancer Center. "The data suggest that CAMPATH may provide an important new treatment option for fludarabine-refractory patients, a group for whom the prognosis has, to date, been extremely poor. While the treatment of patients with leukemia has relied on chemotherapeutic agents, the use of monoclonal antibodies is an innovative approach to circumventing the disease's mechanisms for resistance."

The non-comparative trial, involved 93 previously treated patients who had received prior alkylating agents and failed fludarabine therapy (median of three prior treatment regimens). For these patients, the median life expectancy is usually six to nine months.

In the trial, patients participating at the 20 clinical sites in the United States and Europe received 30 mg of CAMPATH on an outpatient basis, as an intravenous infusion, three times a week, for four to 12 weeks. The dose was gradually escalated over the first week to 30 mg, in or
'"/>

Contact: Deborah Sibley, ILEX Oncology
210-949-8287
Porter Novelli
12-Jun-1999


Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
(Date:8/3/2015)... , ... August 03, 2015 , ... ... ALS and amputation , AUGUST 3, 2015 – Since winning a South by ... 2015, Not Impossible – an organization whose mission is to develop technology for ...
(Date:8/3/2015)... ... 2015 , ... The art of preparing and cooking food comes naturally to ... young age, Nasreen Zereshki was extremely eager to cook Persian cuisine. Now that she ... My Persian Kitchen with the world. , Since Americans tend to be undereducated about ...
(Date:8/3/2015)... ... 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing ... Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker Meridien ... Company’s presentation may be accessed via the investor relations section of the Company’s website. ...
(Date:8/3/2015)... OR (PRWEB) , ... August 03, 2015 , ... ... California’s Modoc National Forest, to Ahjumawi Lava Springs, California’s northernmost and among its ... California’s largest untapped ground water aquifers, whose main outflow is at Ahjumawi Lava ...
(Date:8/3/2015)... ... 2015 , ... A July 9 article from USA Today has ... to the American Dental Association. According to a study by the American Dental Association, ... in a single year to 2.2 million a year. Dentists and ADA officials all ...
Breaking Medicine News(10 mins):Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3
(Date:8/3/2015)... -- VWR (NASDAQ: VWR ), a leading, ... redesign of its global website, www.vwr.com , to improve ... new site, guests will enjoy enhanced content on a modern ... country site now includes: , a simplified ... , the ability to search by discipline/industry. ...
(Date:8/3/2015)... 2015 /OFF HOLD OFF ... PIV757417 The following release: "Biotech Advancements Coupled with ... & Treatments for Critical-Care Patients With Severe Wound ... Aug 2015 12:30 GMT Cooperative research ... research and top-tier universities for identifying biotech solutions ...
(Date:8/3/2015)... JUPITER, Fla. , Aug. 3, 2015 /PRNewswire/ ... announced initiation of its second clinical development program ... drug candidate, CL-H1T.  CL-H1T contains ... is being developed as a treatment for migraine ... "Many patients with migraine headaches ...
Breaking Medicine Technology:VWR's New Website Redesign Provides Improved Functionality for Customers 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2
Cached News: